Related Experiment Video
Updated: Apr 19, 2026

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds
Published on: October 29, 2015
[New drugs for hepatitis C]
1Helsingin yliopisto, kliininen laitos.
Abstract:
Hepatitis C is an important risk factor of hepatocellular carcinoma and in Europe the most common cause of liver transplantation performed due to cirrhosis. Pharmacologic therapy of hepatitis C has long been based on the combination of pegylated interferon and ribavirin. Telaprevir and boseprevir improved the treatment options of relapse patients in particular, but their use has been limited by adverse effects, among other things. The second-generation virus-specific drugs that are now becoming available revolutionize the treatment of hepatitis C. They are orally administrable and as combinations effective against all genotypes. The price of these drugs is, however, notably high.
Related Concept Videos
Hepatitis
Viral Hepatitis I: Introduction
Inhibitors of Viral Protein Synthesis
FDA Approved Drugs: Changes to Approved Drugs
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Retrovirus Life Cycles

